ClinicalTrials.gg
RecruitingNCT05876312PNHUpdated Jun 16, 2026

Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

A Phase 1/2 interventional study of ADX-038 and Placebo in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by ADARx Pharmaceuticals, Inc.. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by ADARx Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia — 2 open to participants now, 3 under way, none of them phase 3. Hemoglobinuria, Paroxysmal · Australia.

Planned enrollment
9th of 12
50 · median 80
Started
2023
with 1 other
Phase 1/2
2 of 15
1 open now
Registered
14th of 15
by date
Lead sponsor
1 of 15
ADARx Pharmaceuticals, Inc.

Among the 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 1/2, and was the 14th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

2 of the 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia, or all of them as a file.
02

Study summary

The first-in-human Phase 1/Phase 2a study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Read the detailed description

The clinical study described in this protocol is a Phase 1/Phase 2a study evaluating safety, tolerability, PK, and PD of ADX-038.

The study consists of 2 parts:

  1. Phase 1 - Randomized, double-blind, placebo-controlled, parallel group, single ascending dose (SAD) in HP with up to 5 dose cohorts.
  2. Phase 2a - Open label, single-arm (ADX-038), 2 dose study in participants with paroxysmal nocturnal hemoglobinuria (PNH) and residual anemia on a standard-of-care (SOC) anti-C5 regimen of ravulizumab or eculizumab.
03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Keywords

  • siRNA
  • PNH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Phase 1 Key Inclusion Criteria

  • 18 to 55 years of age
  • Participants who are healthy as determined by medical evaluation
  • History of recent meningococcal, pneumococcal and Haemophilus influenzae type B vaccinations or willing to be vaccinated
  • Screening tests negative for illicit drug, nicotine, and alcohol use

Phase 1 Key Exclusion Criteria

  • History of any significant medical conditions, except for completely excised non-melanoma skin cancer or low grade cervical intraepithelial neoplasia without evidence of recurrence within the prior 3 months
  • Any viral, bacterial, parasitic, or fungal infection within the prior 30 days
  • Frequent respiratory, nasopharyngeal or ear infections (more than 5 infections per year)
  • History of environmental exposure or sick contact that increase the risk of meningococcal, pneumococcal and/or Haemophilus influenza type B infections
  • Complement deficiency or immunodeficiency syndrome
  • Major surgery or significant traumatic injury within the prior 3 months
  • History of anaphylaxis or reactions
  • History of penicillin allergy
  • History of splenectomy
  • History of alcohol abuse or illicit drug use
  • Donated plasma within the prior 7 days
  • Donated blood or loss more than 400 milliliters of blood (excluding blood volume drawn at screening) within the prior 90 days
  • Screening estimated of less than 60 milliliters per minute
  • Screening hematology, serum chemistry, or coagulation parameters that are outside the normal range
  • Screening vital signs that are abnormal per protocol specification
  • Screening findings that are
  • Pregnant or lactating females
  • Use of prescription (except for and study-related prophylactic antibiotics) or over-the counter medications (except for paracetamol or ibuprofen) or vitamins/supplements within the prior 7 days
  • Use of medications that may reduce the effectiveness of hormonal contraceptives within the prior 28 days
  • Use of an therapeutics within the prior 30 days or within the expected washout (at least 5 half-lives)
  • Unwilling or unable to adhere to study-related prophylactic antibiotics requirements

Phase 2a Key Inclusion Criteria

  • at least 18 years of age
  • Diagnosis of paroxysmal nocturnal hemoglobinuria based on documented clone size
  • concentration of less than 12 gram per deciliter
  • History of recent meningococcal, pneumococcal and Haemophilus influenzae type b vaccinations or willing to be vaccinated
  • On a stable anti-C5 regimen for greater than or equal to 12 weeks prior to Day 1

Phase 2a Key Exclusion Criteria

  • Any viral, bacterial, parasitic, or fungal infection within the prior 14 days
  • , active or infection
  • History of meningococcal or tuberculosis infection
  • History of in the past 5 years, except for completely excised non-melanoma skin cancer or low grade cervical intraepithelial neoplasia with no evidence of recurrence within the prior 3 months
  • Complement deficiency syndrome
  • History of hematopoietic stem cell transplantation
  • History of splenectomy
  • Inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, or chronic liver disease
  • Clinically significant and uncontrolled medical conditions including, but not limited to, thromboembolic disease, acute coronary syndrome, and diabetes
  • Pregnant or lactating females
  • Use of an investigational therapeutics within the prior 30 days or within the expected (at lest 5 half-lives)
  • Abstain from alcohol consumption for 48 hrs before day of dosing and restrict to no more than an average of 14 standard drinks per week
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Phase 1 - Active ADX-038 administered to HP

    For each cohort in Phase 1 (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-038): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.

    Drug: ADX-038

  • Placebo comparator
    Phase 1- Placebo administered to HP

    For each cohort in Phase 1 (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-038): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.

    Drug: Placebo

  • Experimental
    Phase 2a - ADX-038 administered to PNH participants

    This will be initiated at the dose level determined by the Safety Review Committee from SAD in HPs. The treatment of PNH participants is an open-label study.

    Drug: ADX-038

Interventions

  • siRNA duplex oligonucleotide

    Also known as: siRNA

  • DrugPlacebo

    Saline

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Safety in Healthy Volunteers

    To evaluate the safety and tolerability of ADX-038 in HVs by incidence, relationship, and severity of adverse events and serious adverse events

    Time frame: 365 days

  2. Safety in Paroxysmal Nocturnal Hemoglobinuria Participants

    Evaluate the safety and tolerability of ADX-038 by incidence, relationship, and treatment-emergent adverse events and serious adverse events.

    Time frame: 365 days

Secondary outcomes

  1. Pharmacokinetics in Healthy Participants

    To characterize the Pharmacokinetics of ADX-038 in HPs by measuring the Maximum observed plasma concentration (Cmax)

    Time frame: 8 days

  2. Pharmacodynamics in Healthy Participants

    Change from base in plasma concentrations over time in Complement factor B (CFB) protein via assay measurement

    Time frame: 365 days

  3. Pharmacodynamics in Paraxysmal Nocturnal Hemoglobinuria

    Evaluate the changes in hemoglobin concentrations

    Time frame: 365 days

  4. Pharmacodynamics in Paraxysmal Nocturnal Hemoglobinuria

    Characterize the changes in serum concentration of complement factor B (CFB) protein and complement alternative pathway activity level.

    Time frame: 365 days

  5. Pharmacodynamics in Healthy Participants

    Change in complement alternative pathway activity via assay measurement

    Time frame: 365 days

Other outcomes

  1. Immune Response in Healthy Participants

    Anti-polyethylene glycol (PEG) antibody titers and anti-drug antibody titers

    Time frame: 365 days

  2. Pharmacodynamics in Healthy Participants

    Change in complement classical pathway activity via assay measurement

    Time frame: 365 days

  3. Safety in Paroxysmal Nocturnal Hemoglobinuria Participants

    Evaluate the change from baseline in follow up visits for safety assesments

    Time frame: 365 days

  4. Clinical Effect in Paroxysmal Nocturnal Hemoglobinuria Participants

    Look at time (number of days) from dosing (Day 1) to diminished therapeutics effect (DTE)

    Time frame: 365 days

  5. Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants

    Evaluate changes in lactate dehydrogenase (LDH) (U/L)

    Time frame: 365 days

  6. Effects on Hemolysis in Paroxysmal Nocturnal Hemoglobinuria Participants

    Evaluate incidence of clinical breakthrough hemolysis, blood transfusions and Incidence of major adverse vascular events (MAVEs)

    Time frame: 365 days

  7. Pharmacokinetics in Paraxysmal Nocturnal Hemoglobinuria

    Characterize PK parameters of ADX-038 by plasma C(max)

    Time frame: 8 days

  8. Pharmacodynamics in Paraxysmal Nocturnal Hemoglobinuria

    Characterize changes in complement classical pathway activity level

    Time frame: 365 days

  9. Immune Response in Paraxysmal Nocturnal Hemoglobinuria

    Determine Anti-PEG and anti-drug antibody titers

    Time frame: 365 days

  10. Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants

    Evaluate changes in serum free hemoglobin

    Time frame: 365 days

  11. Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants

    Evaluate changes in Haptoglobin Concentrations

    Time frame: 365 days

  12. Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants

    Evaluate changes in Reticulocyte Counts (%)

    Time frame: 365 days

  13. Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants

    Evaluate changes in Bilirubin (umol/L)

    Time frame: 365 days

  14. Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants

    Evaluate changes in Aspartate aminotransferase (U/L)

    Time frame: 365 days

  15. Pharmacokinetics in Paraxysmal Nocturnal Hemoglobinuria

    Characterize PK parameters of ADX-038 by plasma AUC (0-infinity)

    Time frame: 8 days

  16. Pharmacokinetics in Paraxysmal Nocturnal Hemoglobinuria

    Characterize PK parameters of ADX-038 by plasma AUC(0-last)

    Time frame: 8 days

  17. Pharmacokinetics in Paraxysmal Nocturnal Hemoglobinuria

    Characterize PK parameters of ADX-038 by plasma T(max)

    Time frame: 8 days

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Mar 2028, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2023
First posted
May 25, 2023
StartActual
Aug 7, 2023
Primary completionEst.
Mar 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05876312
Lead sponsor
ADARx Pharmaceuticals, Inc.
Collaborators
ADARx Australia Pty Ltd, Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
May 25, 2023
Start date
Aug 7, 2023
Primary completion
Mar 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Jun 16, 2026

Study contacts

Stephanie Leyva
Contact
info@adarx.com
877-232-7974

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ADX-038

Start the discussion